Morgan Stanley
OVID icon

Morgan Stanley’s Ovid Therapeutics OVID Stock Holding History

Morgan Stanley’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Buy
49,555
+12,603
+34% +$22.5K ﹤0.01% 6114
2025
Q4 		$60.2K Buy
36,952
+34,638
+1,497% +$53.4K ﹤0.01% 6377
2025
Q3 		$3.01K Sell
2,314
-8,251
-78% -$7.15K ﹤0.01% 7213
2025
Q2 		$3.48K Sell
10,565
-72,162
-87% -$21.7K ﹤0.01% 7123
2025
Q1 		$25.8K Sell
82,727
-106,760
-56% -$65.6K ﹤0.01% 6474
2024
Q4 		$177K Buy
189,487
+23,657
+14% +$26.5K ﹤0.01% 5837
2024
Q3 		$196K Buy
165,830
+96,880
+141% +$101K ﹤0.01% 5761
2024
Q2 		$53K Sell
68,950
-31,003
-31% -$86.3K ﹤0.01% 6149
2024
Q1 		$305K Sell
99,953
-167,927
-63% -$562K ﹤0.01% 5550
2023
Q4 		$863K Buy
267,880
+224,763
+521% +$768K ﹤0.01% 5368
2023
Q3 		$166K Sell
43,117
-10,527
-20% -$37.8K ﹤0.01% 5668
2023
Q2 		$176K Buy
53,644
+20,782
+63% +$70.6K ﹤0.01% 5701
2023
Q1 		$84.8K Buy
32,862
+29,321
+828% +$69.5K ﹤0.01% 6077
2022
Q4 		$6.59K Sell
3,541
-12,518
-78% -$21.3K ﹤0.01% 7078
2022
Q3 		$30K Sell
16,059
-4,812
-23% -$10.1K ﹤0.01% 6622
2022
Q2 		$45K Buy
20,871
+1,801
+9% +$4.35K ﹤0.01% 6662
2022
Q1 		$60K Sell
19,070
-2,395
-11% -$7.53K ﹤0.01% 6620
2021
Q4 		$69K Sell
21,465
-23,969
-53% -$82.1K ﹤0.01% 6646
2021
Q3 		$153K Sell
45,434
-144,766
-76% -$528K ﹤0.01% 6134
2021
Q2 		$743K Buy
190,200
+112,266
+144% +$443K ﹤0.01% 5256
2021
Q1 		$314K Sell
77,934
-72,179
-48% -$240K ﹤0.01% 5395
2020
Q4 		$347K Buy
150,113
+20,587
+16% +$96K ﹤0.01% 5285
2020
Q3 		$744K Sell
129,526
-21,361
-14% -$143K ﹤0.01% 4417
2020
Q2 		$1.11M Buy
150,887
+28,826
+24% +$135K ﹤0.01% 4086
2020
Q1 		$364K Sell
122,061
-220,115
-64% -$742K ﹤0.01% 4556
2019
Q4 		$1.42M Buy
342,176
+282,933
+478% +$893K ﹤0.01% 4291
2019
Q3 		$192K Buy
59,243
+7,169
+14% +$16.3K ﹤0.01% 5151
2019
Q2 		$96K Sell
52,074
-73,832
-59% -$132K ﹤0.01% 5344
2019
Q1 		$224K Buy
125,906
+87,238
+226% +$218K ﹤0.01% 4996
2018
Q4 		$93K Sell
38,668
-13,099
-25% -$59.8K ﹤0.01% 5581
2018
Q3 		$293K Buy
51,767
+23,105
+81% +$175K ﹤0.01% 5278
2018
Q2 		$223K Buy
28,662
+991
+4% +$8.51K ﹤0.01% 5490
2018
Q1 		$196K Buy
27,671
+1,014
+4% +$8.2K ﹤0.01% 5477
2017
Q4 		$264K Buy
26,657
+19,752
+286% +$181K ﹤0.01% 5310
2017
Q3 		$59K Buy
6,905
+1,848
+37% +$15.4K ﹤0.01% 5736
2017
Q2 		$53K Buy
+5,057
New +$66K ﹤0.01% 5839

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley's OVID Position: Q1 2026 in Review

Morgan Stanley increased its Ovid Therapeutics (OVID) stake by 34% in Q1 2026, buying an estimated $22.5K and bringing the position to 49,555 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #6114.

Morgan Stanley first reported a position in OVID in Q2 2017 and has held it in 36 quarters since. The position peaked at $1.42M in Q4 2019. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Morgan Stanley held 49,555 shares of Ovid Therapeutics worth $110K as of Q1 2026.
  • Morgan Stanley bought 12,603 Ovid Therapeutics shares in Q1 2026, an estimated $22.5K.
  • Ovid Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6114 holding.
  • Morgan Stanley first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 36 quarters since.
  • Morgan Stanley's Ovid Therapeutics position peaked at $1.42M in Q4 2019.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.